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Immune Responses to Varicella-Zoster in the Aged
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\s=b\Skin test reactivity and in vitro lymphocyte stimulation
responses to varicella-zoster (VZ) were examined in a large
normal population ranging in age from 6 months to 93 years.
Waning of cellular immunity, as examined by skin delayed
hypersensitivity, began at age 40 years. Skin test responses to
phytohemagglutinin, however, remained positive into the eighth
decade of life. In vitro lymphocyte stimulation responses to VZ
were usually positive (stimulation index \m=ge\2.5) until age 60
years, after which time levels, as observed with nonimmune
individuals, were often demonstrated. Antibody levels, as mea-
sured by fluorescent antibody to membrane antigen, remained
positive into the ninth and tenth decades of life. This was
especially so with a history of reactivation (zoster) VZ infections,
while skin test and in vitro responses were rarely positive in
those individuals. Thus cellular, as contrasted with humoral,
immunity decreases with advancing age, which may account for
a propensity to reactivation of VZ virus.(Arch Intern Med 1982;142:291-293)
"Drimary varicella-zoster (VZ) is a relatively benign viral
¦*¦ disease recognized clinically as chickenpox, which
infects essentially everyone in this country. The virus
becomes latent, probably in all hosts, to be reactivated at a
later time for reasons as yet poorly understood. The clinical
presentation of reactivation, termed "zoster" or "shin¬
gles," is experienced by an estimated 0.2% to 2% of the
population, most of whom are elderly adults'- or immuno-
suppressed individuals3 who have had chickenpox as chil¬
dren. Immunosuppression may result from underlying
malignant neoplasms such as Hodgkin's disease,' immuno-
suppressive therapy, or both. Depressed cellular immunity
has been documented in such patients. Less well defined is
immune reactivity to specific antigens such as VZ in the
elderly. It is apparent that a better understanding of
changes in immune capabilities as a person ages might
offer insight into control of VZ infection with application
to other groups such as cancer patients. The present
studies were, therefore, designed to investigate both cellu¬
lar and humoral immune response to VZ in age groups
from infancy to very elderly.
MATERIALS AND METHODS
Study Population
Volunteers were selected from employees and outpatients at the
University Hospital Little Rock, Ark, and patients followed up by
the Geriatrics Service at the Little Rock Veterans Administration
Medical Center. Particular emphasis was placed on including only
individuals who were free from an acute or chronic disease that
might affect immunological competence and those with optimal
nutritional status. Institution-approved informed consent was
obtained from each participant so that blood could be drawn and
skin tests applied. Each participant completed all aspects of
testing described below whether or not he was considered immune
to VZ.
Immunological Assays
The following in vivo and in vitro correlates of immune function
were examined: (1) skin testing with VZ antigen and phytohemag-
glutinin (PHA), (2) mitogen (PHA)- and antigen (VZ)-induced
lymphocyte stimulation, and (3) antibody to VZ.
Skin Testing
Varicella-zoster virus antigen was prepared from the Scott
strain of VZ and human diploid cells. Details of its production and
evaluation were described previously.'' Phytohemagglutinin was
purified from a commercial lot of reagent with a total dose of 20 ug
employed for skin testing. A volume of 0.1 mL of VZ antigen,
PHA, or control (normal saline) material was injected intrader-
mally into the forearm, and reactivity was measured at 48 and 72
hours. The maximum response was recorded as millimeters of
erythema or induration. A reaction was considered positive if
induration or erythema was 5 mm or more.
Mitogen- and Antigen-Induced Lymphocyte Stimulation
Lymphocytes were separated from peripheral whole blood by
centrifugation on a Hypaque-Ficoll gradient as previously de¬
scribed." Using a biopipette, 0.1 mL of the lymphocyte suspension(2 x IO"' lymphocytes) was added to an equal volume of various
concentrations of PHA and VZ antigen. A harvesting apparatus,
previously described and technically refined for our use, was
employed for separation of the stimulated lymphocytes on glass-
fiber filters, for washing of these cells, and for recovery of
tritiated thymidine uptake.7 The PHA cultures were incubated for
three days using a five-hour tritiated thymidine pulse and VZ
cultures for five days with a 24-hour pulse. Results are expressed
as a stimulation index: counts per minute of tritiated thymidine
uptake for lymphocytes incubated with PHA or VZ, divided by
counts per minute after incubation with medium alone.
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Fig 1 .—Percent positive skin test responses to varicella-zoster(closed circles) and phytohemagglutinin (PHA) (open circles)
according to age. Skin reactivity considered positive if induration
or erythema was 5 mm or more at 48 or 72 hours.
Varicella-Zoster Antibody
Serum antibody to VZ was measured by fluorescent antibody to
membrane antigen." Briefly, unfixed tissue culture cells were
incubated with various dilutions of test serum, washed, incubated
with fluorescein-labeled antihuman IgG, and examined by fluores¬
cence microscopy. Surface fluorescence at serum dilutions of 1:8 or
more was considered positive.
RESULTS
Skin test reactivity for various age groups is summa¬
rized in Fig 1. No patient demonstrated changes following
injection of normal saline (control negative material).
After age 40 years, the incidence of positive skin test
responses to VZ progressively decreased, while PHA
responses showed consistent delayed hypersensitivity reac¬
tions into the eighth decade of life. Therefore, as judged by
these in vivo assays, immunity to VZ wanes beginning at
40 years of age, while more nonspecific responses may
persist in later years.
In vitro lymphocyte stimulation with PHA supported
previously reported data demonstrating declining reactivi¬
ty with age. Results for subjects in their eighth decade of
life or older had mean counts per minute approximately
half those from volunteers younger than 40 years. Lympho-
Fig 2.—In vitro varicella-zoster (VZ)-induced lymphocyte stimula¬
tion according to age and expressed as stimulation index: counts
per minute of tritiated thymidine uptake for lymphocytes incu¬
bated with VZ, divided by uptake after incubation with medium
alone.
"Expressed as a stimulation index: counts per minute of tritiated
thymidine uptake for lymphocytes incubated with varicella-zoster antigen,
divided by uptake after incubation with medium alone.
cyte proliferation responses, specific for VZ antigen, are
tabulated in Fig 2. Mean values were above control positive
determinations (stimulation index > 2.5) until age 60
years. This suggests adequate immunity for most individ¬
uals until quite late in life. Results are similar for measure¬
ment of VZ antibody. Most "normal" individuals up to age
80 years had protective titers (Table 1).
Elderly patients (60 to 100 years) with a history of
reactivation disease, ie, zoster, usually had measurable
antibody but negative skin test and stimulation responses
to VZ antigen (Fig 1 and 2 and Tables 1 and 2).
COMMENT
Aspects of cellular, immune function in the elderly have
been the subject of previous investigations, with most
suggesting a waning with age. Decreased lymphocyte
stimulation, using either PHA or concanavalin A, has been
documented in a number of reports,"" as well as in the
present one. However, interpretation of these data is
difficult since mitogen stimulation is a rather gross mea¬
surement of immune capability. More recently, similar
results were found using VZ specific lymphoblastoid prolif¬
eration assays.'" The latter study included 14 elderly adults(over 60 years of age), who were compared with 15 young
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subjects (under 35 years of age). This report also demon¬
strated equivalent proliferative responses to other anti¬
gens (streptokinase-streptodornase and PPD), antibody
titers to VZ, and interferon production after stimulation
with VZ.
The present studies attempted to more clearly define the
age at which specific cellular immune reactivity begins to
diminish. Skin testing was included since this test would be
readily applicable in the general clinical setting. It is not
presently apparent whether more complex in vitro assays
would actually offer any advantage over the skin-testing
approach in evaluating cell-mediated immunity to VZ.
With this in vivo screen, waning of immunity was recog¬
nized to begin at about age 40 years (Fig 1). By age 60
years, most individuals had negative skin test responses. In
vitro measurement, on the other hand, suggests that
cellular immunity persists in most individuals until age 60
years (Fig 2), after which time reactivity decreases. This
follows the clinical correlate, ie, propensity to reactivation
disease, more closely than skin test results.
Even after age 80 years, 54% of volunteers manifest
reactions to PHA. Many reactions were only 5 to 10 mm of
erythema without induration, but these would still be
considered positive. Phytohemagglutinin, as a skin test
reagent, has been shown to produce more consistently
positive responses than antigen preparations." More
recently, however, investigations have suggested that
some skin test responses may not be indicative of delayed
hypersensitivity since patients with proven cellular
immune deficiency occasionally manifest erythema or
induration following injection." Thus, the PHA skin test
response may represent a more nonspecific immunological
event. With few exceptions, the only young patients we
have encountered with negative PHA skin test responses
were those with severe primary or secondary immunedeficiency. This has also been the experience for others in
studies of cancer patients.'"' However, a more comprehen¬
sive evaluation of other skin test antigens in the elderly
would better delineate whether decreased cellular immuni¬
ty is a selective one for VZ since PHA does not discrimi¬
nate subtle defects.
In contrast to the decline in cellular immune responses to
VZ with aging, humoral immunity remains relatively
intact. This, once again, refutes the Hope-Simpson hypoth¬
esis'6 that reactivation VZ disease is a consequence of
antibody titers falling below critical levels. Most published
data have also confirmed the presence of antibody both in
the elderly and in patients with zoster.'7
Fourteen elderly volunteers (60 to 100 years) had a
history of shingles, with eight reporting two or more
episodes. The course of this disease tended to be pro¬
tracted, frequently persisting for more than a month. The
most difficult management problem was the pain that
accompanied the vesiculation. None of the 14 patients,
however, were treated with antiviral agents. The VZ
immune function testing in these subjects revealed consis¬
tently high antibody titers, but essentially absent cellular
immune reactivity. Thus, waning of this aspect of host
defense probably accounts for a propensity to reactivation
disease and development of zoster does not appear then to
stimulate conversion of VZ cell-mediated responses. The
individual, therefore, remains predisposed to recurrent
episodes.
The application of these observations to cancer patients
is quite relevant. These patients represent the group at
highest risk to VZ disease and the ones most likely to
require medical intervention for progressive disease.
Depression of cellular immunity is also considered the most
important host factor for predisposition to disease in these
individuals. Treatment trials, such as antiviral chemother¬
apeutic agents, are being examined. Preliminary results
indicate that some aspects of immunotherapy in conjunc¬
tion with antiviral agents may provide the clinical arma¬
mentarium so long awaited for combating this ubiquitous
viral agent.'" An understanding of the immunology of VZ
virus disease is, of course, essential for guiding efforts at
therapy. Combining the present data and our experience
with the same assays in cancer patients,'" it appears that
the immunological status of the aged and the cancer
patient is quite similar and that waning of cellular immu¬
nity to VZ in both groups is related to subsequent viral
reactivation.
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